Lipostatin

Lipostatin (calcium atorvastatin) is indicated for:

Reducing the risk of myocardial infarction;
Reducing the risk of stroke;
Reduce the risk of revascularization procedures and angina pectoris.
In patients with clinically pronounced signs of lesions of the coronary vessels of the heart, lipostatin (calcium atorvastatin) is indicated for:

Reducing the risk of non-fatal myocardial infarction;
Reducing the risk of fatal and non-fatal stroke;
Risk reduction during revascularization procedure;
Reducing the risk of hospitalization due to blockage of the heart vessels;
Reduce the risk of angina.
Lipostatin (calcium atorvastatin) is also recommended in the following cases:

As an adjunct to the diet to reduce elevated total cholesterol, LDL cholesterol, apo-B, and triglyceride levels in individuals with primary hypercholesterolemia (heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia (Fredrickson types II and IIb).
As an adjunct therapy to the diet in the treatment of individuals with elevated serum triglycerides (Fredrickson type IV).
In the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III) in the absence of an adequate response to diet.
To reduce the levels of total cholesterol and LDL cholesterol in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering agents (i.e., AFEREELP), or if such treatment is ineffective.
As a supplement to the diet to reduce the level of total cholesterol, LDL cholesterol and apo-B in boys and girls after the first menstruation, aged 10-17 years, suffering from heterozygous familial hyperlipoproteinemia, if the following signs are present after an adequately selected diet therapy:
1) The LDL-cholesterol level remains ≥ 190 mg/dl or

2) The LDL-cholesterol level remains ≥ 160 mg / dl

3) If the family has observed the occurrence of early heart and vascular diseases, or

4) The calf has two or more other risk factors for developing cardiovascular diseases.